DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Neuromodulation Market

Global Neuromodulation Market Opportunities and Forecast 2020-2027

  • DLR2484
  • 04 August, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Neuromodulation Market, By Technology (Internal neuromodulation [Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation, Other Neuromodulation Technologies], External neuromodulation [Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation]), By Application (Chronic Pain Management, Failed back syndrome, Epilepsy, Tremor, Urinary, and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's disease, Obsessive-Compulsive Disorder, Migraine, Other), By Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), and opportunities and forecast 2020-2027

Neuromodulation Market Overview

Neuromodulation is defined by the International Neuromodulation Society (INS) as a field of science, medicine, and bioengineering that encompasses implantable and non-implantable technologies, electrical or chemical, that impact upon neural interfaces to improve life for humanity. Neurological disorders such as epilepsy, Alzheimer's disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous systems. To manage such disorders, neuromodulation is used. 

The global Neuromodulation Market is mainly driven by the increasing incidence of neurological diseases, such as Alzheimer’s and Parkinson’s diseases across the world. According to World Health Organization, worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. Alzheimer's disease is the most common form of dementia and may contribute to 60–70% of cases. Moreover, other factors such as the rising old age population and their vulnerability for neurological disorders and growing awareness regarding the safety and efficacy of neurostimulator devices are remarkably contributing to the growth of the Neuromodulation Market.

On the other hand, lack of trained healthcare professionals and stringent approval policies, are expected to hamper the growth of the market.

Covid-19 Impact on Neuromodulation Market

In addition, the current Neuromodulation Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Neuromodulation Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Neuromodulation Market Segment Overview

According to technology, the Spinal Cord Stimulation segment has significant growth in the Neuromodulation market. The spinal cord stimulation (SCS) has huge potential to treat widespread chronic back pain. Around 20% of adult Americans experience chronic pain. Recently, USFDA and similar regulatory agencies have approved many products of the SCS technology. The use of technology is expanding to new indications such as failed back surgery syndrome, refractory angina pectoris, peripheral vascular disease, and complex regional pain syndrome.  Additionally, Deep Brain Stimulation (DBS) segment is expected to show noteworthy growth owing to the high adoption rate in developed countries for neurological disorders, such as Parkinson’s disease. The use of DBS is mainly in severe obsessive-compulsive disorder, treatment-resistant depression, Alzheimer's type dementia, and movement disorders.

Neuromodulation Market, By Technology
  • Internal neuromodulation
    • Deep Brain Stimulation
    • Sacral Nerve Stimulation
    • Vagus Nerve Stimulation
    • Spinal Cord Stimulation
    • Other Neuromodulation Technologies
  • External neuromodulation
    • Transcutaneous Electrical Nerve Stimulation
    • Transcranial Magnetic Stimulation
Neuromodulation Market, By Application

·       Chronic Pain Management
·       Failed back syndrome
·       Epilepsy
·       Tremor
·       Urinary and Fecal Incontinence
·       Depression
·       Dystonia
·       Gastroparesis
·       Parkinson's disease
·       Obsessive-Compulsive Disorder
·       Migraine
·       Other

Neuromodulation Market, By Biomaterial

·       Metallic Biomaterials
·       Polymeric Biomaterials
·       Ceramic Biomaterials

Neuromodulation Regional Overview

Region-wise, North America is the most significant region in the global neuromodulation market and is anticipated to be the first preference for new competitors due to the increasing end-use in the region. Similarly, the market in the Asia Pacific is anticipated to expand at a rapid pace in the coming years. Factors such as government and private initiatives to increase awareness regarding mental health and increasing incidences of neurological disorders boost the market’s growth in the Asia Pacific.  In addition to this, Japan has the highest revenue share in the region, followed by China. India is expected to witness rapid growth in the future due to increasing awareness regarding mental disorders and growing expenditure in the healthcare sector.

Neuromodulation Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)

Neuromodulation Market Competitor overview

Some key developments and strategies adopted by manufacturers in Neuromodulation are highlighted below.

·       In July 2021, Merck KGaA has tapped a Spanish startup to help it build a new approach to bioelectronic therapies. The aim is to use graphene to target multiple chronic diseases through selective nerve stimulation.

Neuromodulation Market, Key Players

·       Medtronic plc
·       St. Jude Medical, Inc.
·       LivaNova PLC
·       Boston Scientific Corporation
·       Aleva Neurotherapeutics SA
·       BioControl Medical
·       Bioness Inc.
·       EnteroMedics Inc
·       Nevro Corporation and NeuroPace Inc.

Neuromodulation Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Technology
        • 5.2.1. Internal neuromodulation
          • 5.2.1.1. Deep Brain Stimulation
          • 5.2.1.2. Sacral Nerve Stimulation
          • 5.2.1.3. Vagus Nerve Stimulation
          • 5.2.1.4. Spinal Cord Stimulation
          • 5.2.1.5. Other Neuromodulation Technologies
        • 5.2.2. External neuromodulation
          • 5.2.2.1. Transcutaneous Electrical Nerve Stimulation
          • 5.2.2.2. Transcranial Magnetic Stimulation
    • 5.3. Market Analysis, Insights and Forecast – By Application
      • 5.3.1. Chronic Pain Management
      • 5.3.2. Failed back syndrome
      • 5.3.3. Epilepsy
      • 5.3.4. Tremor
      • 5.3.5. Urinary and Fecal Incontinence
      • 5.3.6. Depression
      • 5.3.7. Dystonia
      • 5.3.8. Gastroparesis
      • 5.3.9. Parkinson's disease
      • 5.3.10. Obsessive-Compulsive Disorder
      • 5.3.11. Migraine
      • 5.3.12. Other
    • 5.4. Market Analysis, Insights and Forecast – By Biomaterial
      • 5.4.1. Metallic Biomaterials
      • 5.4.2. Polymeric Biomaterials
      • 5.4.3. Ceramic Biomaterials
    • 5.5. Market Analysis, Insights and Forecast – By Region
      • 5.5.1. North America
      • 5.5.2. Europe
      • 5.5.3. Asia Pacific
      • 5.5.4. Latin America, Middle East and Africa
    • 6. North America Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Technology
        • 6.2.1. Internal neuromodulation
          • 6.2.1.1. Deep Brain Stimulation
          • 6.2.1.2. Sacral Nerve Stimulation
          • 6.2.1.3. Vagus Nerve Stimulation
          • 6.2.1.4. Spinal Cord Stimulation
          • 6.2.1.5. Other Neuromodulation Technologies
        • 6.2.2. External neuromodulation
          • 6.2.2.1. Transcutaneous Electrical Nerve Stimulation
          • 6.2.2.2. Transcranial Magnetic Stimulation
    • 6.3. Market Analysis, Insights and Forecast – By Application
      • 6.3.1. Chronic Pain Management
      • 6.3.2. Failed back syndrome
      • 6.3.3. Epilepsy
      • 6.3.4. Tremor
      • 6.3.5. Urinary and Fecal Incontinence
      • 6.3.6. Depression
      • 6.3.7. Dystonia
      • 6.3.8. Gastroparesis
      • 6.3.9. Parkinson's disease
      • 6.3.10. Obsessive-Compulsive Disorder
      • 6.3.11. Migraine
      • 6.3.12. Other
    • 6.4. Market Analysis, Insights and Forecast – By Biomaterial
      • 6.4.1. Metallic Biomaterials
      • 6.4.2. Polymeric Biomaterials
      • 6.4.3. Ceramic Biomaterials
    • 6.5. Market Analysis, Insights and Forecast – By Country
      • 6.5.1. U.S.
      • 6.5.2. Canada
    • 7. Europe Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Technology
        • 7.2.1. Internal neuromodulation
          • 7.2.1.1. Deep Brain Stimulation
          • 7.2.1.2. Sacral Nerve Stimulation
          • 7.2.1.3. Vagus Nerve Stimulation
          • 7.2.1.4. Spinal Cord Stimulation
          • 7.2.1.5. Other Neuromodulation Technologies
        • 7.2.2. External neuromodulation
          • 7.2.2.1. Transcutaneous Electrical Nerve Stimulation
          • 7.2.2.2. Transcranial Magnetic Stimulation
    • 7.3. Market Analysis, Insights and Forecast – By Application
      • 7.3.1. Chronic Pain Management
      • 7.3.2. Failed back syndrome
      • 7.3.3. Epilepsy
      • 7.3.4. Tremor
      • 7.3.5. Urinary and Fecal Incontinence
      • 7.3.6. Depression
      • 7.3.7. Dystonia
      • 7.3.8. Gastroparesis
      • 7.3.9. Parkinson's disease
      • 7.3.10. Obsessive-Compulsive Disorder
      • 7.3.11. Migraine
      • 7.3.12. Other
    • 7.4. Market Analysis, Insights and Forecast – By Biomaterial
      • 7.4.1. Metallic Biomaterials
      • 7.4.2. Polymeric Biomaterials
      • 7.4.3. Ceramic Biomaterials
    • 7.5. Market Analysis, Insights and Forecast – By Country
      • 7.5.1. UK
      • 7.5.2. Germany
      • 7.5.3. France
      • 7.5.4. Italy
      • 7.5.5. Spain
      • 7.5.6. Russia
      • 7.5.7. Rest of Europe
    • 8. Asia Pacific Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Technology
        • 8.2.1. Internal neuromodulation
          • 8.2.1.1. Deep Brain Stimulation
          • 8.2.1.2. Sacral Nerve Stimulation
          • 8.2.1.3. Vagus Nerve Stimulation
          • 8.2.1.4. Spinal Cord Stimulation
          • 8.2.1.5. Other Neuromodulation Technologies
        • 8.2.2. External neuromodulation
          • 8.2.2.1. Transcutaneous Electrical Nerve Stimulation
          • 8.2.2.2. Transcranial Magnetic Stimulation
    • 8.3. Market Analysis, Insights and Forecast – By Application
      • 8.3.1. Chronic Pain Management
      • 8.3.2. Failed back syndrome
      • 8.3.3. Epilepsy
      • 8.3.4. Tremor
      • 8.3.5. Urinary and Fecal Incontinence
      • 8.3.6. Depression
      • 8.3.7. Dystonia
      • 8.3.8. Gastroparesis
      • 8.3.9. Parkinson's disease
      • 8.3.10. Obsessive-Compulsive Disorder
      • 8.3.11. Migraine
      • 8.3.12. Other
    • 8.4. Market Analysis, Insights and Forecast – By Biomaterial
      • 8.4.1. Metallic Biomaterials
      • 8.4.2. Polymeric Biomaterials
      • 8.4.3. Ceramic Biomaterials
    • 8.5. Market Analysis, Insights and Forecast – By Country
      • 8.5.1. China
      • 8.5.2. India
      • 8.5.3. Japan
      • 8.5.4. Australia
      • 8.5.5. South East Asia
      • 8.5.6. Rest of Asia Pacific
    • 9. Latin America, Middle East and Africa Neuromodulation Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Technology
        • 9.2.1. Internal neuromodulation
          • 9.2.1.1. Deep Brain Stimulation
          • 9.2.1.2. Sacral Nerve Stimulation
          • 9.2.1.3. Vagus Nerve Stimulation
          • 9.2.1.4. Spinal Cord Stimulation
          • 9.2.1.5. Other Neuromodulation Technologies
        • 9.2.2. External neuromodulation
          • 9.2.2.1. Transcutaneous Electrical Nerve Stimulation
          • 9.2.2.2. Transcranial Magnetic Stimulation
    • 9.3. Market Analysis, Insights and Forecast – By Application
      • 9.3.1. Chronic Pain Management
      • 9.3.2. Failed back syndrome
      • 9.3.3. Epilepsy
      • 9.3.4. Tremor
      • 9.3.5. Urinary and Fecal Incontinence
      • 9.3.6. Depression
      • 9.3.7. Dystonia
      • 9.3.8. Gastroparesis
      • 9.3.9. Parkinson's disease
      • 9.3.10. Obsessive-Compulsive Disorder
      • 9.3.11. Migraine
      • 9.3.12. Other
    • 9.4. Market Analysis, Insights and Forecast – By Biomaterial
      • 9.4.1. Metallic Biomaterials
      • 9.4.2. Polymeric Biomaterials
      • 9.4.3. Ceramic Biomaterials
    • 9.5. Market Analysis, Insights and Forecast – By Country
      • 9.5.1. Brazil
      • 9.5.2. Saudi Arabia
      • 9.5.3. UAE
      • 9.5.4. Rest of LAMEA
    • 10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Medtronic plc
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. St. Jude Medical, Inc.
      • 10.6. LivaNova PLC
      • 10.7. Boston Scientific Corporation
      • 10.8. Aleva Neurotherapeutics SA
      • 10.9. BioControl Medical
      • 10.10. Bioness Inc.
      • 10.11. EnteroMedics Inc
      List of Figures

      Figure 1: Global Neuromodulation Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Neuromodulation Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Neuromodulation Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Neuromodulation Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Neuromodulation Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Neuromodulation Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Neuromodulation Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Neuromodulation Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Neuromodulation Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Neuromodulation Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Neuromodulation Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Neuromodulation Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Neuromodulation Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Neuromodulation Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Neuromodulation Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Neuromodulation Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Neuromodulation Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Neuromodulation Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Neuromodulation Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Neuromodulation Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Neuromodulation Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Neuromodulation Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Neuromodulation Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934